KR20020036665A - 한쪽방향성의 단일가닥 디엔에이 절편들을 이용하는재조합 디엔에이 라이브러리의 제조방법 - Google Patents
한쪽방향성의 단일가닥 디엔에이 절편들을 이용하는재조합 디엔에이 라이브러리의 제조방법 Download PDFInfo
- Publication number
- KR20020036665A KR20020036665A KR1020010041549A KR20010041549A KR20020036665A KR 20020036665 A KR20020036665 A KR 20020036665A KR 1020010041549 A KR1020010041549 A KR 1020010041549A KR 20010041549 A KR20010041549 A KR 20010041549A KR 20020036665 A KR20020036665 A KR 20020036665A
- Authority
- KR
- South Korea
- Prior art keywords
- polynucleotide
- recombinant
- stranded
- starting
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 113
- 239000012634 fragment Substances 0.000 title claims abstract description 93
- 108020004511 Recombinant DNA Proteins 0.000 title claims abstract description 67
- 108020004414 DNA Proteins 0.000 title description 134
- 102000053602 DNA Human genes 0.000 title description 43
- 108020004682 Single-Stranded DNA Proteins 0.000 title description 36
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 164
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 164
- 239000002157 polynucleotide Substances 0.000 claims abstract description 164
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 91
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 44
- 239000007858 starting material Substances 0.000 claims abstract description 37
- 238000006243 chemical reaction Methods 0.000 claims abstract description 31
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 28
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 23
- 239000013598 vector Substances 0.000 claims abstract description 20
- 239000013612 plasmid Substances 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 18
- 108091008146 restriction endonucleases Proteins 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 14
- 108010052305 exodeoxyribonuclease III Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 11
- 239000000376 reactant Substances 0.000 claims description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 108060002716 Exonuclease Proteins 0.000 claims description 5
- 102000004157 Hydrolases Human genes 0.000 claims description 5
- 108090000604 Hydrolases Proteins 0.000 claims description 5
- 102000013165 exonuclease Human genes 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 108010068698 spleen exonuclease Proteins 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 102000004195 Isomerases Human genes 0.000 claims description 2
- 108090000769 Isomerases Proteins 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 210000004507 artificial chromosome Anatomy 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- -1 antibodies Proteins 0.000 claims 2
- 239000003999 initiator Substances 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 1
- 238000005215 recombination Methods 0.000 abstract description 31
- 230000006798 recombination Effects 0.000 abstract description 31
- 125000003729 nucleotide group Chemical group 0.000 abstract description 17
- 239000002773 nucleotide Substances 0.000 abstract description 16
- 238000000338 in vitro Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 102000008300 Mutant Proteins Human genes 0.000 abstract description 4
- 108010021466 Mutant Proteins Proteins 0.000 abstract description 4
- 230000001131 transforming effect Effects 0.000 abstract 1
- 108010089807 chitosanase Proteins 0.000 description 34
- 108010022172 Chitinases Proteins 0.000 description 30
- 102000012286 Chitinases Human genes 0.000 description 15
- 239000006142 Luria-Bertani Agar Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 241000607720 Serratia Species 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920002101 Chitin Polymers 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 238000012270 DNA recombination Methods 0.000 description 4
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 102220215697 rs200971068 Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091028733 RNTP Proteins 0.000 description 2
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000014639 sexual reproduction Effects 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000149420 Bothrometopus brevis Species 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000042812 Divales Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
- HDRRAMINWIWTNU-PRJDIBJQSA-N [[(5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CCC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-PRJDIBJQSA-N 0.000 description 1
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical class N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
| 키티나아제 | 비활성 (U/mg) |
| 세라티아 마르세센스 키티나아제 | 150.6 |
| 세라티아 리큐파션스 키티나아제 | 201.3 |
| R-24 키티나아제 | 227.2 |
| 키토산아제 변이체 | 아미노산 치환부위 |
| d10-68 | D305G |
| e3-97 | E308G |
| e4-12 | I389M |
| e15-20 | T131I, N368D |
| e18-5 | S24P, T277A, N368D |
| e22-23 | K172E, S376P |
| e26-27 | Q159R |
| e26-98 | E107D, Q442R |
| e30-97 | S376P, Y451C |
| 변이 키토산아제 | 아미노산 치환부위 |
| M-13 키토산아제 | N60Y, E107D, Q159R, N228T, D305G, E308G, N368D,S376P, F384L, I389M, D435G |
| M-20 키토산아제 | S24P, E107D, Q159R, N286D, D305G, E308G, N357D,N368D, N371D |
Claims (17)
- 다음과 같은 단계를 포함하는 재조합 폴리뉴클레오티드의 제조 방법:(a) 재조합시키고자 하는 한 종류 이상의 상동성있는 출발 폴리뉴클레오티드로부터 다양한 길이를 갖는 한쪽방향성 단일가닥 폴리뉴클레오티드 절편들의 풀(pool)을 제조하는 단계;(b) 복수의 주기적인 연장 반응을 포함하는 중합과정을 수행하는 단계로서,단계 (a)에서 제조된 한쪽방향성 단일가닥 폴리뉴클레오티드 절편들이 순차적으로 주형으로 작용하고, 여기에 특정 올리고뉴클레오티드가 시발물질로서 첨가되며, 이 프라이머들이 주형교환(template switching)을 통해 연장되어 적어도 한 종류 이상의 재조합 폴리뉴클레오티드를 생산하고, 제조된 재조합 폴리뉴클레오티드는 출발 폴리뉴클레오티드와 염기서열이 상이한 것을 특징으로 하는 단계; 및(c) 한 종류 이상의 특정 시발물질을 사용하여 상기 (b) 단계에서 제조된 재조합 폴리뉴클레오티드를 증폭하는 연쇄중합반응을 수행하는 단계.
- 제1항에 있어서, 상기 (a) 단계는(i) 한 종류 이상의 출발 폴리뉴클레오티드로부터 RNA를 제조하기 위해 전사 과정을 수행하는 단계; 및(ii) 무작위 올리고뉴클레오티드를 시발물질로 하고 상기 (i)단계에서 얻어진 RNA 전사물을 주형으로 하여 역전사반응(reverse transcription)을 수행하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계는(i) 출발 이중가닥 폴리뉴클레오티드를 하나 이상의 제한효소로 처리하여 폴리뉴클레오티드의 두 말단중 한쪽 말단을 돌출된 3' 말단 구조로 만드는 단계;(ii) 상기 (i)단계의 반응 혼합물에 엑소뉴클레아제-Ⅲ를 처리하고 일정한 시간 간격으로 반응물을 취한 후 엑소뉴클레아제 Ⅲ의 반응을 중지시킴으로써 한쪽 방향으로 순차적으로 절단된 구조의 이중가닥 폴리뉴클레오티드의 풀을 제조하는 단계;(iii) 돌출된 5' 말단 구조를 갖는 상기 (ii)단계에서 생성된 이중가닥 폴리뉴클레오티드에 S1 뉴클리아제와 DNA 중합효소를 처리하여 평활(blunt) 말단을 갖도록 전환시키는 단계;(iv) (i)단계에서 돌출된 3' 말단 구조를 가졌던 이중가닥 폴리뉴클레오티드의 동일한 말단을 새로운 돌출된 3' 말단 구조로 만드는 단계; 및(v) 상기 (iv)단계의 폴리뉴클레오티드에 엑소뉴클레아제 Ⅲ를 처리하여 단일가닥 폴리뉴클레오티드 절편을 제조하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계는(i) 출발 이중가닥 폴리뉴클레오티드를 하나 이상의 제한효소로 처리하여 한쪽 말단을 돌출된 3' 말단 구조로 만드는 단계;(ii) 상기 (i)단계에서 생성된 폴리뉴클레오티드에 엑소뉴클레아제 Ⅲ를 처리하여단일가닥 폴리뉴클레오티드를 제조하는 단계; 및(iii) 무작위 프라이머를 사용하여 상기 (ii)단계의 단일가닥 폴리뉴클레오티드를 주형으로 중합반응을 수행하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계는(i) 출발 이중가닥 폴리뉴클레오티드를 하나 이상의 제한효소로 처리하여 한쪽 말단을 돌출된 3' 말단 구조로 만드는 단계;(ii) 상기 (i)단계에서 생성된 폴리뉴클레오티드에 엑소뉴클레아제 Ⅲ를 처리하여 단일가닥 폴리뉴클레오티드를 제조하는 단계; 및(iii) (ii)단계에서 얻어진 단일가닥 폴리뉴클레오티드에 단일가닥 특이적 5'→3' 엑소뉴클레아제를 처리하고 일정한 시간 간격으로 반응물을 취한 후 엑소뉴클레아제의 반응을 중지시킴으로써 한쪽 방향으로 순차적으로 절단된 구조를 갖는 단일가닥 폴리뉴클레오티드의 풀을 제조하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계는(i) 정방향(forward) 혹은 역방향(reverse) 중 한 종류의 올리고뉴클레오티드 시발물질만을 사용하여 출발 이중가닥 폴리뉴클레오티드를 주형으로 중합효소 연쇄반응을 실시하는 단계;(ii) 생성된 단일가닥 폴리뉴클레오티드를 출발 이중가닥 폴리뉴클레오티드로부터 분리하는 단계; 및(iii) 무작위 시발물질을 사용하여 상기 (ii)단계의 단일가닥 폴리뉴클레오티드를 주형으로 중합반응을 수행하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계는(i) 정방향(forward) 혹은 역방향(reverse) 중 한 종류의 올리고뉴클레오티드 시발물질만을 사용하여 출발 이중가닥 폴리뉴클레오티드를 주형으로 중합효소 연쇄반응을 실시하는 단계;(ii) 생성된 단일가닥 폴리뉴클레오티드를 출발 이중가닥 폴리뉴클레오티드로부터 분리하는 단계; 및(iii) (ii)단계에서 얻어진 단일가닥 폴리뉴클레오티드에 단일가닥 특이적 5'→3' 엑소뉴클레아제를 처리하고 일정한 시간 간격으로 반응물을 취한 후 엑소뉴클레아제의 반응을 중지시킴으로써 한쪽 방향으로 순차적으로 절단된 구조를 갖는 단일가닥 폴리뉴클레오티드의 풀을 제조하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계는(i) 적어도 한 종류 이상의 출발 폴리뉴클레오티드가 삽입된 바이러스 벡터나 플라스미드 벡터로부터 단일가닥의 폴리뉴클레오티드를 추출하는 단계; 및(ii) 무작위 올리고뉴클레오티드를 시발물질로 하여 상기 (i)단계의 단일가닥 폴리뉴클레오티드를 주형으로 중합반응을 일으키는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (b)단계는(i) 적어도 한 주기의 중합반응에서 시발물질이 주형으로 이용된 한쪽방향성 단일가닥 폴리뉴클레오티드 절편의 말단까지 중합반응을 통해 길이가 신장되는 단계;(ii) 다음에 계속되는 적어도 한 주기의 연쇄중합반응에서 (i)단계에서 신장된 각 폴리뉴클레오티드가 주형교환을 통해 (i)단계에서 사용된 주형 폴리뉴클레오티드 절편과는 다른 한쪽방향성 단일가닥 폴리뉴클레오티드 절편의 말단까지 길이가 더 신장되는 단계; 및(iii) 목적하는 길이의 재조합 폴리뉴클레오티드가 얻어질 때까지 상기 (ii)단계를 반복하는 단계를 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (b)단계의 특정 올리고뉴클레오티드 시발물질은 적어도 한 종류의 출발 폴리뉴클레오티드와 하이브리드화할 수 있는 염기서열을 갖는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a) 단계의 출발 폴리뉴클레오티드는 효소, 항체, 항원, 결합단백질, 호르몬, 성장인자 및 혈장단백질로 이루어진 그룹으로부터 선택된 어느 하나의 단백질을 암호화하는 유전자 또는 그 일부인 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 효소는 가수분해효소(hydrolase), 분해효소(lyase), 전달효소(transferase), 산화환원효소(oxidoreductase), 연결효소(ligase) 및 이성화효소(isomerase)로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (a)단계의 출발 폴리뉴클레오티드는 야생형 또는 이로부터 비롯된 돌연변이 폴리뉴클레오티드인 방법.
- 제1항 내지 제10항 중 어느 한 항의 방법에 의해 제조된 재조합 폴리뉴클레오티드를 벡터에 삽입하여 재조합 벡터를 제조하고, 이 재조합 벡터를 발현세포에 도입하여 복수의 돌연변이 클론을 제조하는 단계를 포함하는 재조합 DNA 라이브러리의 제조 방법.
- 제14항에 있어서, 상기 벡터는 파아지, 플라스미드, 파아지미드, 바이러스 벡터 및 인공염색체 등으로 구성된 군으로부터 선택되는 방법.
- 제14항에 있어서, 상기 발현세포가 세균, 곰팡이, 식물세포, 동물세포 및 곤충세포로 구성된 군으로부터 선택되는 방법.
- 제14항의 방법에 의해 제조된 재조합 DNA 라이브러리로부터 원하는 기능적 특성을 지닌 재조합 폴리뉴클레오티드를 선발하는 과정을 포함하는, 폴리뉴클레오티드를 원하는 성질을 갖도록 진화시키는 방법.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20000066889 | 2000-11-10 | ||
| KR1020000066889 | 2000-11-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20020036665A true KR20020036665A (ko) | 2002-05-16 |
| KR100446417B1 KR100446417B1 (ko) | 2004-09-04 |
Family
ID=19698438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2001-0041549A Expired - Lifetime KR100446417B1 (ko) | 2000-11-10 | 2001-07-11 | 한쪽방향성의 단일가닥 디엔에이 절편들을 이용하는 재조합 디엔에이 라이브러리의 제조방법 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6955879B2 (ko) |
| JP (1) | JP3777158B2 (ko) |
| KR (1) | KR100446417B1 (ko) |
| AU (1) | AU2001274635A1 (ko) |
| WO (1) | WO2002038757A1 (ko) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014066179A1 (en) * | 2012-10-24 | 2014-05-01 | Clontech Laboratories, Inc. | Template switch-based methods for producing a product nucleic acid |
| US9719136B2 (en) | 2013-12-17 | 2017-08-01 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| US10941397B2 (en) | 2013-10-17 | 2021-03-09 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| KR20210117223A (ko) * | 2020-06-23 | 2021-09-28 | (주) 하임바이오텍 | 순차적 중합효소 연쇄 반응용 조성물 및 이를 이용한 유전자 증폭 방법 |
| KR20220118333A (ko) * | 2021-02-18 | 2022-08-25 | 서울대학교산학협력단 | 핵산 라이브러리의 정제방법 |
| KR20230121012A (ko) * | 2022-02-10 | 2023-08-17 | 주식회사 에이티지라이프텍 | 핵산 라이브러리의 정제방법 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7153655B2 (en) | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
| US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| US7262012B2 (en) | 2002-05-17 | 2007-08-28 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations |
| EP1527173A1 (en) * | 2002-07-23 | 2005-05-04 | Nuevolution A/S | Gene shuffing by template switching |
| AU2009322346B2 (en) | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
| CN112175954B (zh) * | 2020-10-19 | 2022-09-09 | 复旦大学附属肿瘤医院 | Iv类脱氧核酶突变体及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994368A (en) * | 1987-07-23 | 1991-02-19 | Syntex (U.S.A.) Inc. | Amplification method for polynucleotide assays |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5965408A (en) * | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US5962271A (en) * | 1996-01-03 | 1999-10-05 | Cloutech Laboratories, Inc. | Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end |
| US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| KR100430534B1 (ko) * | 2001-05-23 | 2004-05-10 | 주식회사 마이크로아이디 | 단일가닥 디엔에이 분해효소를 이용하여 키메라 디엔에이라이브러리를 만드는 방법 |
-
2001
- 2001-06-16 AU AU2001274635A patent/AU2001274635A1/en not_active Abandoned
- 2001-06-16 JP JP2002542073A patent/JP3777158B2/ja not_active Expired - Fee Related
- 2001-06-16 WO PCT/KR2001/001031 patent/WO2002038757A1/en not_active Ceased
- 2001-06-16 US US10/148,724 patent/US6955879B2/en not_active Expired - Lifetime
- 2001-07-11 KR KR10-2001-0041549A patent/KR100446417B1/ko not_active Expired - Lifetime
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11001882B2 (en) | 2012-10-24 | 2021-05-11 | Takara Bio Usa, Inc. | Template switch-based methods for producing a product nucleic acid |
| US9410173B2 (en) | 2012-10-24 | 2016-08-09 | Clontech Laboratories, Inc. | Template switch-based methods for producing a product nucleic acid |
| US12454721B2 (en) | 2012-10-24 | 2025-10-28 | Takara Bio Usa, Inc. | Template switch-based methods for producing a product nucleic acid |
| WO2014066179A1 (en) * | 2012-10-24 | 2014-05-01 | Clontech Laboratories, Inc. | Template switch-based methods for producing a product nucleic acid |
| US10941397B2 (en) | 2013-10-17 | 2021-03-09 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| US10954510B2 (en) | 2013-10-17 | 2021-03-23 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| US10415087B2 (en) | 2013-12-17 | 2019-09-17 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| US11124828B2 (en) | 2013-12-17 | 2021-09-21 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| US9719136B2 (en) | 2013-12-17 | 2017-08-01 | Takara Bio Usa, Inc. | Methods for adding adapters to nucleic acids and compositions for practicing the same |
| KR20210117223A (ko) * | 2020-06-23 | 2021-09-28 | (주) 하임바이오텍 | 순차적 중합효소 연쇄 반응용 조성물 및 이를 이용한 유전자 증폭 방법 |
| KR20220118333A (ko) * | 2021-02-18 | 2022-08-25 | 서울대학교산학협력단 | 핵산 라이브러리의 정제방법 |
| KR20230121012A (ko) * | 2022-02-10 | 2023-08-17 | 주식회사 에이티지라이프텍 | 핵산 라이브러리의 정제방법 |
| KR20250057708A (ko) * | 2022-02-10 | 2025-04-29 | 주식회사 에이티지라이프텍 | 핵산 라이브러리의 정제방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001274635A1 (en) | 2002-05-21 |
| US20030152943A1 (en) | 2003-08-14 |
| JP3777158B2 (ja) | 2006-05-24 |
| WO2002038757A1 (en) | 2002-05-16 |
| JP2004513633A (ja) | 2004-05-13 |
| US6955879B2 (en) | 2005-10-18 |
| KR100446417B1 (ko) | 2004-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2308292C (en) | Method of dna shuffling | |
| JP4689940B2 (ja) | ヘテロ二本鎖の相補性を増大させる方法 | |
| US7816085B2 (en) | Method for in vitro molecular evolution of protein function | |
| KR100446417B1 (ko) | 한쪽방향성의 단일가닥 디엔에이 절편들을 이용하는 재조합 디엔에이 라이브러리의 제조방법 | |
| US7262012B2 (en) | Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations | |
| EP1341909B1 (en) | A method for in vitro molecular evolution of protein function | |
| US6455254B1 (en) | Sequence based screening | |
| US8071289B2 (en) | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules | |
| Lee et al. | A new approach to directed gene evolution by recombined extension on truncated templates (RETT) | |
| AU2006314310B2 (en) | A method for in vitro molecular evolution of protein function | |
| KR100475305B1 (ko) | 단일가닥 특이적인 dna 절단효소 엑소뉴클리아제ⅶ을 이용하여 키메라 dna 라이브러리를 만드는 방법 | |
| US20060057567A1 (en) | Method for constructing a chimeric dna library using a single strand speific dnase | |
| EP1548113B1 (en) | A method for obtaining circular mutated and/or chimaeric polynucleotides | |
| US20030092023A1 (en) | Method of shuffling polynucleotides using templates | |
| EP1381680A1 (en) | Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides | |
| JP2004081020A (ja) | キメラ遺伝子の作製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20010711 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20031103 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20040529 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20040825 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20040826 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20070730 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20080822 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090825 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100825 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110825 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20120824 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120824 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20130625 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130625 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20140724 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140724 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160810 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160810 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20170821 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170821 Start annual number: 14 End annual number: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20180717 Year of fee payment: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180717 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200720 Start annual number: 17 End annual number: 17 |
|
| PC1801 | Expiration of term |
Termination date: 20220111 Termination category: Expiration of duration |